Are COPD and cardiovascular disease fundamentally intertwined?

European Respiratory Journal

Volumn 47, Issue 5, 2016, Pages 1307-1309

  Bafadhel, Mona ^a   Russell, Richard E K ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

DESMOSINE;

ARTERIAL STIFFNESS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHRONIC OBSTRUCTIVE LUNG DISEASE; COMORBIDITY; DISEASE ASSOCIATION; EDITORIAL; HUMAN; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR;

CARDIOVASCULAR DISEASES; HUMANS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RISK FACTORS;

EID: 84969850293     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/13993003.00399-2016     Document Type: Editorial

References (31)

1. Sin DD. Is COPD really a cardiovascular disease? Chest 2009; 136: 329-330.
2. Mannino DM, Thorn D, Swenson A, et al. Prevalence and outcomes of diabetes, hypertension and cardiovascular disease in COPD. Eur Respir J 2008; 32: 962-969.
3. Anthonisen NR, Connett JE, Kiley JP, et al. Effects of smoking intervention and the use of an inhaled anticholinergic bronchodilator on the rate of decline of FEV1. The Lung Health Study. JAMA 1994; 272: 1497-1505.
4. McGarvey LP, John M, Anderson JA, et al. Ascertainment of cause-specific mortality in COPD: operations of the TORCH Clinical Endpoint Committee. Thorax 2007; 62: 411-415.
5. Sin DD, Anthonisen NR, Soriano JB, et al. Mortality in COPD: role of comorbidities. Eur Respir J 2006; 28: 1245-1257.
6. Sidney S, Sorel M, Quesenberry CP Jr, et al. COPD and incident cardiovascular disease hospitalizations and mortality: Kaiser Permanente Medical Care Program. Chest 2005; 128: 2068-2075.
7. Quint JK, Herrett E, Bhaskaran K, et al. Effect of β blockers on mortality after myocardial infarction in adults with COPD: population based cohort study of UK electronic healthcare records. BMJ 2013; 347: f6650.
8. Agusti A, Bel E, Thomas M, et al. Treatable traits: Toward precision medicine of chronic airway diseases. Eur Respir J 2016; 47: 410-419.
9. Rabinovich RA, Miller BE, Wrobel K, et al. Circulating desmosine levels do not predict emphysema progression but are associated with cardiovascular risk and mortality in COPD. Eur Respir J 2016; 47: 1365-1373.
10. Luisetti M, Ma S, Iadarola P, et al. Desmosine as a biomarker of elastin degradation in COPD: current status and future directions. Eur Respir J 2008; 32: 1146-1157.
11. Wang H, Liu X, Umino T, et al. Cigarette smoke inhibits human bronchial epithelial cell repair processes. Am J Respir Cell Mol Biol 2001; 25: 772-779.
12. Bracke KR, D'hulst AI, Maes T, et al. Cigarette smoke-induced pulmonary inflammation and emphysema are attenuated in CCR6-deficient mice. J Immunol 2006; 177: 4350-4359.
13. Drost EM, Skwarski KM, Maes T, et al. Oxidative stress and airway inflammation in severe exacerbations of COPD. Thorax 2005; 60: 293-300.
14. Russell RE, Culpitt SV, DeMatos C, et al. Release and activity of matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 by alveolar macrophages from patients with chronic obstructive pulmonary disease. Am J Respir Cell Mol Biol 2002; 26: 602-609.
15. Iwamoto H, Yokoyama A, Kitahara Y, et al. Airflow limitation in smokers is associated with subclinical atherosclerosis. Am J Respir Crit Care Med 2009; 179: 35-40.
16. John ME, Cockroft JR, McKeever TM, et al. Cardiovascular and inflammatory effects of simvastatin therapy in patients with COPD: A randomized controlled trial. Int J Chron Obstruct Pulmon Dis 2015; 10: 211-221.
17. Criner GJ, Connett JE, Aaron SD, et al. Simvastatin for the prevention of exacerbations in moderate-to-severe COPD. N Engl J Med 2014; 370: 2201-2210.
18. Dornhorst AC. Respiratory insufficiency. Lancet 1955; 268: 1185-1187.
19. O'Donnell DE, Laveneziana P. Physiology and consequences of lung hyperinflation in COPD. Eur Respir Rev 2006; 15: 61-67.
20. Vanfleteren LE, Connett JE, Aaron SD, et al. Arterial stiffness in patients with COPD: The role of systemic inflammation and the effects of pulmonary rehabilitation. Eur Respir J 2014; 43: 1306-1315.
21. Mills NL, Miller JJ, Anand A, et al. Increased arterial stiffness in patients with chronic obstructive pulmonary disease: A mechanism for increased cardiovascular risk. Thorax 2008; 63: 306-311.
22. Payne RA, Wilkinson IB, Webb DJ. Arterial stiffness and hypertension: emerging concepts. Hypertension 2010; 55: 9-14.
23. Greenwald SE. Ageing of the conduit arteries. J Pathol 2007; 211: 157-172.
24. Murphy G, Docherty AJP. The matrix metalloproteinases and their inhibitors. Am J Respir Cell Mol Biol 1992; 7: 120-125.
25. Lindberg CA, Engström G, de Verdier MG, et al. Total desmosines in plasma and urine correlate with lung function. Eur Respir J 2012; 39: 839-845.
26. Sherratt MJ. Tissue elasticity and the ageing elastic fibre. Age 2009; 31: 305-325.
27. Shapiro SD, Endicott SK, Province MA, et al. Marked longevity of human lung parenchymal elastic fibers deduced from prevalence of D-aspartate and nuclear weapons-related radiocarbon. J Clin Invest 1991; 87: 1828-1834.
28. Toyama BH, Hetzer MW. Protein homeostasis: live long, won't prosper. Nat Rev Mol Cell Biol 2013; 14: 55-61.
29. Ito K, Barnes PJ. COPD as a disease of accelerated lung aging. Chest 2009; 135: 173-180.
30. Vrhovski B, Weiss AS. Biochemistry of tropoelastin. Eur J Biochem 1998; 258: 1-18.
31. Gettins PGW. Serpin structure, mechanism, and function. Chem Rev 2002; 102: 4751-4804.